Skip to content

Effect of Citrullus Colocynthis Schrad in diabetes

Effect of Citrullus Colocynthis Schrad comparison with Plasebo on dyslipidemia in 2 type diabetic patients: Clinical trial double blind

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20140505017585N3
Enrollment
70
Registered
2018-02-13
Start date
2017-01-04
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabete. Diabetes mellitus

Interventions

Intervention 1: Handal Capsule 125 mg orally, With combinations of restitute (Tragacanth, Starch, Arabic Gum, Fennel All Equal 25 mg)
Once a day before of lunch
for 2 months. Preparation of this capsule is carried out at the Faculty of Pharmacy of Traditional Medicine University of Tehran. Intervention 2: Placebo capsule 125 mg orally, includes Tragacanth and
for 2 months.

Sponsors

Sabzevar University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria were: being diabetic Type 2 for at least 1 year; Having uncontrolled blood lipids (LDL level greater than 100 mg/dl) at least 4 months before the beginning of study and receiving Statins as well as low fat diet; Being younger than 65 and older than 40 years old; Having dossier in the diabetes clinic; The patient's willingness to participate in the research;

Exclusion criteria

Exclusion criteria: Exclusion criteria were: Having Chronic physical disorders like cardiovascular diseases, respiratory, liver, and or ,, , , the and body mass index Having previous history of paroxysm; Surgery on the digestive and Kidney system; BMI lower than 18.5 and higher than 25; Unwillingness to continue cooperation; Death or sick travel; Being pregnant or breastfeeding; Create unwanted drug side effects; Do not take medicine for more than a week; Occurrence of a stressful event in life;

Design outcomes

Primary

MeasureTime frame
Cholesterol. Timepoint: Blood test in begining of study and Three months after the intervention began. Method of measurement: Blood test.;Triglyceride. Timepoint: Blood test in begining of study and Three months after the intervention began. Method of measurement: Blood test.;LDL. Timepoint: Blood test in begining of study and Three months after the intervention began. Method of measurement: Blood test.;HDL. Timepoint: Blood test in begining of study and Three months after the intervention began. Method of measurement: Blood test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBarghamadi Bita

Sabzevar University of Medical Sciences

bitakiyavash@gmail.com+98 51 4464 5620

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026